Therapy News and Research

RSS

Pfizer, Bristol-Myers Squibb receive FDA CRL for ELIQUIS NDA

Bristol-Myers Squibb Company and Pfizer announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for ELIQUIS (apixaban) for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.

25 Jun 2012

Positive results from Lexicon’s LX4211 Phase 2b trial on type 2 diabetes

Lexicon Pharmaceuticals, Inc., announced today that LX4211, an investigational, oral, dual inhibitor of sodium glucose transporters 1 and 2 (SGLT1 and SGLT2), showed substantial, dose-dependent, statistically-significant reductions in hemoglobin A1c (HbA1c) in a Phase 2b trial in patients diagnosed with poorly-controlled type 2 diabetes who were concurrently treated with metformin, an established diabetes therapy.

25 Jun 2012

Study reveals previously unknown function of Thbd-aPC pathway in radiation mitigation

New research in Nature Medicine shows that boosting a protein pathway in the body's blood making system protects mice from otherwise fatal radiation poisoning.

25 Jun 2012

De novo somatic gene mutations likely to cause hemimegalencephaly

Hemimegalencephaly is a rare but dramatic condition in which the brain grows asymmetrically, with one hemisphere becoming massively enlarged. Though frequently diagnosed in children with severe epilepsy, the cause of hemimegalencephaly is unknown and current treatment is radical: surgical removal of some or all of the diseased half of the brain.

25 Jun 2012

Overactive thyroid gland may increase risk of hospitalization for heart and blood-vessel disease

An overactive thyroid gland, or hyperthyroidism, may increase the risk of hospitalization for heart and blood-vessel disease even after surgery to remove the gland, according to a new study. The results will be presented Saturday at The Endocrine Society's 94th Annual Meeting in Houston.

25 Jun 2012

GI Dynamics announces clinical data about EndoBarrier Therapy at ASMBS meeting

GI Dynamics, Inc. announced today that clinical data about EndoBarrier Therapy, a breakthrough treatment for type 2 diabetes and/or obesity, was presented at the 29th Annual Meeting of the American Society for Metabolic & Bariatric Surgery (ASMBS) in San Diego.

23 Jun 2012

Deferasirox reduces elevated iron levels in patients with myelodysplastic syndrome

Researchers at Moffitt Cancer Center and colleagues at six other institutions have recently tested a treatment for patients with myelodysplastic syndrome, or MDS, a blood-related malignancy that involves the ineffective production of blood cells, leaving patients anemic and in need of frequent blood transfusions. Because the body has no natural means to reduce iron that accumulates from repeated transfusions, patients' organs can become iron overloaded, leading to heart failure, liver injury, susceptibility to infection, and other complications.

23 Jun 2012

GMCSF linked with rapid cognitive recovery in patients with cancer

Growth factors shown to cure Alzheimer's disease in a mouse model and administered to cancer patients as part of their treatment regimen were linked to significant improvements in the patients' cognitive function following stem cell transplantation, a preliminary clinical study reports.

23 Jun 2012

Scientists recommend new type of therapeutic approach to dementia

Scientists at Charité - Universitätsmedizin Berlin have succeeded in recommending a new type of therapeutic approach to dementia. The study published in the journal Neurology shows that immune reactions against the body's own nerve cells can be the cause of advanced dementia and an appropriate immune suppressive therapy can develop with significant effectiveness.

23 Jun 2012

WCMC researchers devise innovative boxer-like strategy to fight multiple myeloma

Weill Cornell Medical College researchers have devised an innovative boxer-like strategy, based on the serial use of two anti-cancer drugs, to deliver a one-two punch to first weaken the defenses of multiple myeloma and then deliver the final knock-out punch to win the fight.

23 Jun 2012

Genentech's Perjeta helps people with HER2-positive metastatic breast cancer live longer

Genentech, a member of the Roche Group, announced today that people with HER2-positive metastatic breast cancer (mBC) lived significantly longer (overall survival) when treated with the combination of Perjeta (pertuzumab), Herceptin (trastuzumab) and docetaxel chemotherapy, compared to Herceptin and docetaxel chemotherapy alone in the Phase III CLEOPATRA study.

23 Jun 2012

Disorganized cancers more difficult to treat and consistently result in lower survival rates

Medical researchers at the University of Alberta reviewed test results from thousands of patients with various types of cancer and discovered that "disorganized" cancers were more difficult to treat and consistently resulted in lower survival rates.

23 Jun 2012

Cedars-Sinai educational conference to focus on patient empowerment

Brain tumor patients, families and caregivers are invited to an educational conference that will focus on patient empowerment June 23 at Cedars-Sinai Medical Center.

23 Jun 2012

EMA CHMP adopts positive opinion for Seebri Breezhaler to treat COPD

Sosei Group Corporation confirms the information released today by Novartis that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Seebri Breezhaler (glycopyrronium/NVA237) 44 mcg delivered dose (50 mcg glycopyrronium per capsule), as a once-daily inhaled maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).

23 Jun 2012

EC grants marketing authorization for AMAG's ferumoxytol to treat IDA

AMAG Pharmaceuticals, Inc. today announced that the European Commission has granted marketing authorization for ferumoxytol, an intravenous (IV) iron therapy to treat iron deficiency anemia (IDA) in adult patients with chronic kidney disease (CKD).

23 Jun 2012

Researchers uncover why ointment and photodynamic therapy cause pain in skin cancer patients

Apply the ointment, light on, light off - that's how easy it is to cure various forms of non-melanoma skin cancer. However, the majority of patients suffer severe pain during the so-termed photodynamic therapy.

23 Jun 2012

‘Take home’ methadone maintenance therapy has added benefits

Patients who are given “take home” methadone maintenance treatment for opioid dependence are less likely to be admitted to hospital than those who do not, a study shows.

22 Jun 2012

ATS task force recommends annual lung cancer screening using LDCT

A lung screening and surveillance task force, established by the American Association for Thoracic Surgery (AATS) and led by medical professionals from Brigham and Women's Hospital (BWH), is strongly recommending new guidelines for lung cancer screening. The guidelines were published this week in the online edition of the Journal of Thoracic and Cardiovascular Surgery (JTCVS).

22 Jun 2012

European CHMP adopts positive opinion for teduglutide to treat short bowel syndrome

Takeda Pharmaceutical Company Limited and NPS Pharmaceuticals, Inc., jointly announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product teduglutide (Revestive) as a once-daily treatment for adult patients with short bowel syndrome (SBS).

22 Jun 2012

Wraparound knee brace for osteoarthritis patients

Breg, Inc., a premier provider of sports medicine products and services, has introduced five new products, including a first-of-its-kind wraparound knee brace for osteoarthritis (OA) patients. New products also include two ankle braces designed to help prevent ankle injury, a cold therapy system with longer ice time, and an upgrade to Breg's inventory management system created specifically for the orthopedic office.

22 Jun 2012

Therapy News and Research

Pfizer, Bristol-Myers Squibb receive FDA CRL for ELIQUIS NDA

Positive results from Lexicon’s LX4211 Phase 2b trial on type 2 diabetes

Study reveals previously unknown function of Thbd-aPC pathway in radiation mitigation

De novo somatic gene mutations likely to cause hemimegalencephaly

Overactive thyroid gland may increase risk of hospitalization for heart and blood-vessel disease

GI Dynamics announces clinical data about EndoBarrier Therapy at ASMBS meeting

Deferasirox reduces elevated iron levels in patients with myelodysplastic syndrome

GMCSF linked with rapid cognitive recovery in patients with cancer

Scientists recommend new type of therapeutic approach to dementia

WCMC researchers devise innovative boxer-like strategy to fight multiple myeloma

Genentech's Perjeta helps people with HER2-positive metastatic breast cancer live longer

Disorganized cancers more difficult to treat and consistently result in lower survival rates

Cedars-Sinai educational conference to focus on patient empowerment

EMA CHMP adopts positive opinion for Seebri Breezhaler to treat COPD

EC grants marketing authorization for AMAG's ferumoxytol to treat IDA

Researchers uncover why ointment and photodynamic therapy cause pain in skin cancer patients

‘Take home’ methadone maintenance therapy has added benefits

ATS task force recommends annual lung cancer screening using LDCT

European CHMP adopts positive opinion for teduglutide to treat short bowel syndrome

Wraparound knee brace for osteoarthritis patients

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News